DK3166973T3 - Immunstimulerende monoklonale antistoffer mod human interleukin-2 - Google Patents
Immunstimulerende monoklonale antistoffer mod human interleukin-2 Download PDFInfo
- Publication number
- DK3166973T3 DK3166973T3 DK15759938.2T DK15759938T DK3166973T3 DK 3166973 T3 DK3166973 T3 DK 3166973T3 DK 15759938 T DK15759938 T DK 15759938T DK 3166973 T3 DK3166973 T3 DK 3166973T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunstimulating
- monoclonal antibodies
- antibodies against
- against human
- human interleukin
- Prior art date
Links
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title 1
- 102000055277 human IL2 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176619 | 2014-07-10 | ||
| PCT/IB2015/055226 WO2016005950A1 (en) | 2014-07-10 | 2015-07-10 | Immune-stimulating monoclonal antibodies against human interleukin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3166973T3 true DK3166973T3 (da) | 2020-04-06 |
Family
ID=51162588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15759938.2T DK3166973T3 (da) | 2014-07-10 | 2015-07-10 | Immunstimulerende monoklonale antistoffer mod human interleukin-2 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10894828B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3166973B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7209464B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106604932B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015287227B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2954476C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3166973T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2779977T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016005950A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260218B2 (en) * | 2016-01-11 | 2023-04-01 | Novartis Ag | Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins |
| EP3518969A2 (en) | 2016-09-28 | 2019-08-07 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
| GB201621806D0 (en) * | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| EP3585404A4 (en) * | 2017-02-23 | 2021-04-14 | City of Hope | METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD) |
| EA201992248A1 (ru) * | 2017-03-23 | 2020-02-06 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
| RU2745451C1 (ru) * | 2017-05-25 | 2021-03-25 | Инститьют Фор Бейсик Сайенс | Антитела к человеческому интерлейкину-2 и их применение |
| CN112020510B (zh) | 2018-03-19 | 2024-10-11 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| EP4090377A1 (en) | 2020-01-13 | 2022-11-23 | Synaffix B.V. | Conjugates of antibodies an immune cell engagers |
| EP4103607A4 (en) * | 2020-02-16 | 2023-12-20 | Aulos Bioscience, Inc | MODIFIED ANTI-IL-2 ANTIBODIES |
| AU2021327147A1 (en) * | 2020-08-18 | 2023-04-06 | Universität Zürich | A CD25-biased anti-IL-2 antibody |
| CN117157107A (zh) | 2021-02-08 | 2023-12-01 | 西纳福克斯股份有限公司 | 多功能抗体 |
| KR20240082411A (ko) | 2021-10-14 | 2024-06-10 | 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. | 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도 |
| US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
| CN119775409B (zh) * | 2025-03-05 | 2025-07-11 | 深圳真实生物医药科技有限公司 | 靶向sost的抗体及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340853C (en) * | 1983-12-23 | 1999-12-21 | Hsiang-Fu Kung | Purification of recombinant interleukin-2 |
| JPS62269698A (ja) * | 1986-03-17 | 1987-11-24 | エフ．ホフマン ― ラ ロシュ アーゲー | Ｉｌ−２蛋白質に対するモノクロ−ナル抗体 |
| CA2263129C (en) | 1996-08-16 | 2007-01-09 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ATE386802T1 (de) | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
| WO2004060319A2 (en) | 2002-12-30 | 2004-07-22 | 3M Innovative Properties Company | Immunostimulatory combinations |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| NZ563213A (en) * | 2005-06-01 | 2009-07-31 | Micromet Ag | Anti-IL2 antibodies |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| JP2009527500A (ja) * | 2006-02-16 | 2009-07-30 | ナセント・バイオロジックス・インコーポレイテッド | 免疫機能を改善するための方法および哺乳動物対象における疾患の防止または処置のための方法 |
| CN101045923B (zh) * | 2006-03-31 | 2011-11-23 | 沈阳三生制药有限责任公司 | 生产一种白细胞介素类似物的方法 |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| SI3042917T1 (en) | 2010-08-12 | 2018-04-30 | Eli Lilly And Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
| HUE040326T2 (hu) | 2011-02-10 | 2019-03-28 | Roche Glycart Ag | Mutáns interleukon-2 polipeptidek |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
-
2015
- 2015-07-10 WO PCT/IB2015/055226 patent/WO2016005950A1/en not_active Ceased
- 2015-07-10 EP EP15759938.2A patent/EP3166973B1/en active Active
- 2015-07-10 EP EP20158066.9A patent/EP3693389B1/en active Active
- 2015-07-10 US US15/324,468 patent/US10894828B2/en active Active
- 2015-07-10 AU AU2015287227A patent/AU2015287227B2/en not_active Ceased
- 2015-07-10 DK DK15759938.2T patent/DK3166973T3/da active
- 2015-07-10 ES ES15759938T patent/ES2779977T3/es active Active
- 2015-07-10 CA CA2954476A patent/CA2954476C/en active Active
- 2015-07-10 CN CN201580048027.0A patent/CN106604932B/zh active Active
- 2015-07-10 JP JP2017501280A patent/JP7209464B2/ja active Active
- 2015-07-10 ES ES20158066T patent/ES2989669T3/es active Active
-
2020
- 2020-12-22 US US17/131,221 patent/US20210230269A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7209464B2 (ja) | 2023-01-20 |
| WO2016005950A1 (en) | 2016-01-14 |
| EP3693389C0 (en) | 2024-09-04 |
| CN106604932B (zh) | 2024-12-10 |
| CA2954476A1 (en) | 2016-01-14 |
| ES2779977T3 (es) | 2020-08-21 |
| US10894828B2 (en) | 2021-01-19 |
| EP3166973A1 (en) | 2017-05-17 |
| EP3693389B1 (en) | 2024-09-04 |
| AU2015287227A1 (en) | 2017-02-09 |
| US20170183403A1 (en) | 2017-06-29 |
| US20210230269A1 (en) | 2021-07-29 |
| EP3166973B1 (en) | 2020-02-19 |
| JP2017525343A (ja) | 2017-09-07 |
| EP3693389A1 (en) | 2020-08-12 |
| EP3693389A9 (en) | 2021-04-07 |
| CN106604932A (zh) | 2017-04-26 |
| AU2015287227B2 (en) | 2021-02-18 |
| ES2989669T3 (es) | 2024-11-27 |
| CA2954476C (en) | 2023-09-19 |
| AU2015287227A8 (en) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| IL272227A (en) | Anti-tigit antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| DK3166973T3 (da) | Immunstimulerende monoklonale antistoffer mod human interleukin-2 | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| SI3354729T1 (sl) | Protitelesa anti-garp | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| EP3684806A4 (en) | NEW ANTI-CD3EPSILON ANTIBODIES | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL291164A (en) | Anti-nme antibody | |
| PL3215530T3 (pl) | Ulepszone przeciwciała anty-il-6 | |
| DK3154583T3 (da) | Humane monoklonale antistoffer mod gangliosid gd2 | |
| PL3484921T3 (pl) | Przeciwciała anty-il-22r | |
| DK3452515T3 (da) | Her-2-bindende antistoffer | |
| DK3126391T3 (da) | ANTISTOFFER MOD HPA-1a | |
| LT3178931T (lt) | Anti-orai1 antikūnas |